Inventor · disambiguated record
Nitin K. Damle
Also filed as: DAMLE NITIN · DAMLE NITIN K · DAMLE NITIN KRISHNAJI
30 granted patents·25 pending applications·3,183 citations·filing 1991–2024
98Inventor score
Files withBRISTOL MYERS SQUIBB CO20WYETH CORP10SUN PHARMA ADVANCED RES CO LTD8ASANA BIOSCIENCES LLC5WYETH LLC4
Top patents by PatentIndex Score
55 records- 0199US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0298US5844095ACTLA4 Ig fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 1, 1998·417 cites·2 claims
- 0398US5434131AChimeric CTLA4 receptor and methods for its useBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jul 18, 1995·374 cites·8 claims
- 0497US5968510ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 19, 1999·157 cites·1 claims
- 0597US5885796ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 23, 1999·199 cites·12 claims
- 0697US5580756AB7Ig fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Dec 3, 1996·238 cites·3 claims
- 0797US5521288ACD28IG fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted May 28, 1996·233 cites·2 claims
- 0896US7311910B2Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Dec 25, 2007·40 cites·9 claims
- 0996US5851795ASoluble CTLA4 molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 22, 1998·182 cites·21 claims
- 1096US5770197AMethods for regulating the immune response using B7 binding molecules and IL4-binding moleculesBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 23, 1998·200 cites·11 claims
- 1195US8153768B2Calicheamicin derivative-carrier conjugatesKUNZ ARTHUR·Filed 2003·Granted Apr 10, 2012·114 cites·5 claims
- 1295US8044178B2Anti-5T4 antibodies and uses thereofWYETH LLC·Filed 2007·Granted Oct 25, 2011·41 cites·31 claims
- 1395US5709859AMixed specificity fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1991·Granted Jan 20, 1998·143 cites·22 claims
- 1494US6830937B1Method for generating and identifying antibodies directed against a B7BRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 14, 2004·39 cites·5 claims
- 1593US6887471B1Method to inhibit T cell interactions with soluble B7BRISTOL MYERS SQUIBB CO·Filed 1999·Granted May 3, 2005·66 cites·5 claims
- 1693US5885579ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·122 cites·11 claims
- 1791US8759495B2Anti-5T4 antibodies and uses thereofBOGHAERT ERWIN R·Filed 2011·Granted Jun 24, 2014·22 cites·33 claims
- 1891US7572772B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 11, 2009·10 cites·6 claims
- 1990US6641809B1Method of regulating cellular processes mediated by B7 and CD28BRISTOL MYERS SQUIBB CO·Filed 1994·Granted Nov 4, 2003·84 cites·16 claims
- 2088US8835611B2Calicheamicin derivative-carrier conjugatesKUNZ ARTHUR·Filed 2012·Granted Sep 16, 2014·10 cites·40 claims
- 2184US11434278B2Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2019·Granted Sep 6, 2022·1 cites·4 claims
- 2283US10849887B2Treatment of Parkinson's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2017·Granted Dec 1, 2020·2 cites·7 claims
- 2383US9902771B2Anti-5T4 antibodies and uses thereofWYETH LLC·Filed 2015·Granted Feb 27, 2018·3 cites·20 claims
- 2482US10316080B2Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2014·Granted Jun 11, 2019·4 cites·4 claims
- 2582US9351986B2Calicheamicin derivative-carrier conjugatesWYETH HOLDINGS LLC·Filed 2014·Granted May 31, 2016·4 cites·22 claims
- 2680US8747857B2Calicheamicin derivative-carrier conjugatesKUNZ ARTHUR·Filed 2003·Granted Jun 10, 2014·10 cites·96 claims
- 2777US2024066014A1Treatment for parkinson's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2023·Application pending·0 cites
- 2874US11813252B2Treatment for Parkinson's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2022·Granted Nov 14, 2023·0 cites·4 claims
- 2974US7070776B1Methods for blocking binding of CD28 receptor to B7BRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jul 4, 2006·20 cites·7 claims
- 3074US2023183326A1Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 3170US2009317397A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 3268US11583522B2Treatment for Parkinson's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2020·Granted Feb 21, 2023·0 cites·3 claims
- 3365US2010173382A1Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugatesWYETH CORP·Filed 2009·Application pending·0 cites
- 3464US2018339058A1Calicheamicin derivative-carrier conjugatesWYETH HOLDINGS LLC·Filed 2018·Application pending·0 cites
- 3564US2025041437A1Humanized muc1 antibody and antibody drug conjugateSUN PHARMA ADVANCED RES CO LTD·Filed 2024·Application pending·0 cites
- 3664US2009105461A1Calicheamicin conjugatesWYETH CORP·Filed 2008·Application pending·0 cites
- 3764US2010021483A1Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugatesWYETH CORP·Filed 2009·Application pending·0 cites
- 3862US2014308302A1Anti-5t4 antibodies and uses thereofWYETH LLC·Filed 2014·Application pending·0 cites
- 3961US2018162937A1Anti-5t4 antibodies and uses thereofWYETH LLC·Filed 2018·Application pending·0 cites
- 4061US2024082417A1Protein-polymer drug conjugatesASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 4157US2016303252A1Calicheamicin derivative-carrier conjugatesWYETH HOLDINGS LLC·Filed 2016·Application pending·0 cites
- 4256US2007190060A1Passive targeting of cytotoxic agentsWYETH CORP·Filed 2005·Application pending·0 cites
- 4356US2025275953A1Vodobatinib for reducing progression of parkinson's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2023·Application pending·0 cites
- 4455US2006002942A1Calicheamicin conjugatesWYETH CORP·Filed 2005·Application pending·0 cites
- 4555US2006088522A1Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugatesWYETH CORP·Filed 2005·Application pending·0 cites
- 4653US2022257582A1Treatment for synucleinopathiesSUN PHARMA ADVANCED RES CO LTD·Filed 2020·Application pending·0 cites
- 4752US5861151ASoluble fusion molecules with binding specificity for cell adhesion moleculesBRISTOL MYERS SQUIBB CO·Filed 1991·Granted Jan 19, 1999·10 cites·17 claims
- 4851US2003219446A1Ligand for CD28 receptor on B cells and methodsBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 4949US2009304590A1Therapeutic compositions and methodsWYETH CORP·Filed 2008·Application pending·0 cites
- 5049US2023301982A1N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's diseaseSUN PHARMA ADVANCED RES CO LTD·Filed 2021·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nitin K. Damle files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →